Epstein-Barrvirusearlyantigendiffuse(EBV-EA/D)-directedimmunoglobulinA antibodies in systemic lupus erythematosus patients

Scandinavian Journal of Rheumatology

Volumn 41, Issue 4, 2012, Pages 280-289

  Draborg, A H ^a   Jorgensen J M ^a   Muller H ^a   Nielsen, C T ^a   Jacobsen, S ^b   Iversen, L V ^c   Theander, E ^d   Nielsen, L P ^a   Houen, G ^a   Duus, K ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIBODY; EARLY ANTIGEN DIFFUSE ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG; EPSTEIN BARR VIRUS EARLY ANTIGEN DIFFUSE COMPONENT; EPSTEIN-BARR VIRUS EARLY ANTIGEN DIFFUSE COMPONENT; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DENMARK; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCLERODERMA; SEROLOGY; SJOEGREN SYNDROME; SWEDEN; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; IMMUNOLOGY; MIDDLE AGED; VIROLOGY;

ADULT; AGED; ANTIGENS, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 84863972379     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2012.665944     Document Type: Article

References (50)

1. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257-68.
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39. (Pubitemid 351397092)
3. Smith PP, Gordon C. Systemic lupus erythematosus: clinical presentations. Autoimmun Rev 2010;10:43-5.
4. vonMuhlenCA, Tan EM.Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24: 323-58.
5. Munoz LE, Janko C, Schulze C, Schorn C, Sarter K, Schett G, et al. Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev 2010; 10:38-42.
6. James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001;44:1122-6. (Pubitemid 32433618)
7. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. J Immunol 2005;174:6599-607. (Pubitemid 40705620)
8. Kang I, Quan T, Nolasco H, Park SH, Hong MS, Crouch J, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004;172:1287-94. (Pubitemid 38113792)
9. Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH, et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 2004;6:R295-302.
10. Yu SF,WuHC, TsaiWC,Yen JH,ChiangW,Yuo CY, et al. Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Med Microbiol Immunol 2005;194:115-20. (Pubitemid 41202527)
11. Berner BR, Tary-Lehmann M, Yonkers NL, Askari AD, Lehmann PV, Anthony DD. Phenotypic and functional analysis of EBVspecific memory CD8 cells in SLE. Cell Immunol 2005;235:29-38. (Pubitemid 41483031)
12. Tsokos GC, Magrath IT, Balow JE. Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol 1983;131:1797-801. (Pubitemid 13006895)
13. Auwaerter PG. Infectious mononucleosis in middle age. J Am Med Assoc 1999;281:454-9. (Pubitemid 29069444)
14. Tattevin P, Le TY, Minjolle S, Person A, Chapplain JM, Arvieux C, et al. Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis: surveillance study. J Clin Microbiol 2006;44:1873-4. (Pubitemid 43726289)
15. Joseph AM, Babcock GJ, Thorley-Lawson DA. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 2000;74:9964-71.
16. Babcock GJ, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000;13:497-506.
17. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82. (Pubitemid 33741978)
18. Schepers A, Pich D, Hammerschmidt W. Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1. Virology 1996;220:367-76. (Pubitemid 26201693)
19. Holley-Guthrie EA, Quinlivan EB, Mar EC, Kenney S. The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol 1990;64:3753-9. (Pubitemid 20227199)
20. Zhang Q, Hong Y, Dorsky D, Holley-Guthrie E, Zalani S, Elshiekh NA, et al. Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: effects on EBV transcription and lytic replication. J Virol 1996;70:5131-42. (Pubitemid 26240684)
21. Quinlivan EB, Holley-Guthrie EA, Norris M, Gutsch D, Bachenheimer SL, Kenney SC. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res 1993;21:1999-2007. (Pubitemid 23178921)
22. Zhang Q, Holley-Guthrie E, Ge JQ, Dorsky D, Kenney S. The Epstein-Barr virus (EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream component of the EBV oriLyt. Virology 1997;230:22-34. (Pubitemid 27243519)
23. Wong KM, Levine AJ. Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans. J Virol 1986;60:149-56. (Pubitemid 16003156)
24. Luka J, Miller G, Jornvall H, Pearson GR. Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein. J Virol 1986;58:748-56. (Pubitemid 16082761)
25. Chen LW, Lin LS, Chang YS, Liu ST. Functional analysis of EA-D of Epstein-Barr virus. Virology 1995;211:593-7.
26. Tsurumi T. Purification and characterization of the DNA-binding activity of the Epstein-Barr virus DNA polymerase accessory protein BMRF1 gene products, as expressed in insect cells by using the baculovirus system. J Virol 1993;67:1681-7. (Pubitemid 23067680)
27. Tsurumi T, Daikoku T, Kurachi R, Nishiyama Y. Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro. J Virol 1993;67:7648-53. (Pubitemid 23343898)
28. Li JS, Zhou BS, Dutschman GE, Grill SP, Tan RS, Cheng YC. Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity. J Virol 1987;61: 2947-9. (Pubitemid 17143463)
29. Daibata M, Sairenji T. Epstein-Barr virus (EBV) replication and expressions of EA-D (BMRF1 gene product), virus-specific deoxyribonuclease, and DNA polymerase in EBV-activated Akata cells. Virology 1993;196:900-4.
30. Jones JF, Straus SE. Chronic Epstein-Barr virus infection. Annu Rev Med 1987;38:195-209.
31. Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 2008;22:883-96.
32. Ooka T, de Turenne-Tessier M, Stolzenberg MC. Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases. Springer Semin Immunopathol 1991;13:233-47.
33. Schwarzmann F, Jager M, Hornef M, Prang N, Wolf H. Epstein- Barr viral gene expression in B-lymphocytes. Leuk Lymphoma 1998;30:123-9. (Pubitemid 28327261)
34. Chen DY, Chen YM, Lan JL, Chen HH, Hsieh CW, Wey SJ, et al. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-Barr virus connection? J Clin Virol 2010; 49:290-5.
35. Huggins ML, Todd I, Powell RJ. Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. Rheumatol Int 2005;25:183-7. (Pubitemid 40576782)
36. Berkun Y, Zandman-Goddard G, Barzilai O, Boaz M, Sherer Y, Larida B, et al. Infectious antibodies in systemic lupus erythematosus patients. Lupus 2009;18:1129-35.
37. Stratta P, Canavese C, Ciccone G, Santi S, Quaglia M, Ghisetti V, et al. Correlation between cytomegalovirus infection and Raynaud's phenomenon in lupus nephritis. Nephron 1999;82:145-54. (Pubitemid 29263974)
38. Lu JJ, Chen DY, Hsieh CW, Lan JL, Lin FJ, Lin SH. Association of Epstein-Barr virus infection with systemic lupus erythematosus in Taiwan. Lupus 2007;16:168-75. (Pubitemid 46506593)
39. Chen CJ, Lin KH, Lin SC, Tsai WC, Yen JH, Chang SJ, et al. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. J Rheumatol 2005;32:44-7.
40. Parks CG, Cooper GS, Hudson LL, Dooley MA, Treadwell EL, St Clair EW, et al. Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum 2005;52:1148-59. (Pubitemid 40530122)
41. Esen BA, Yilmaz G, Uzun S, Ozdamar M, Aksozek A, Kamali S, et al. Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. Rheumatol Int 2012;32:79-83.
42. Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, Blank M, Ram M, et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci 2009;1173:658-63.
43. Lau CS, Yuen KY, Chan KH, Wong RW. Lack of evidence of active lytic replication of Epstein-Barr and cytomegaloviruses in patients with systemic lupus erythematosus. Chin Med J (Engl) 1998;111:660-5.
44. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
45. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23: 581-90.
46. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
47. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
48. Liu MT, Lin LS, Yu Y, Chung TT, Hsu CY, Chen JT, et al. Use of recombinant Epstein-Barr virus early antigen for detection of antibody in patients with nasopharyngeal carcinoma. Zhonghua Yi Xue Za Zhi (Taipei) 1996;57:7-15. (Pubitemid 126732913)
49. Chang KP, Hsu CL, Chang YL, Tsang NM, Chen CK, Lee TJ, et al. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol 2008;44:784-92.
50. Paramita DK, Fachiroh J, Artama WT, van Benthm E, Haryana SM, Middeldorp JM. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. J Med Virol 2007;79:1710-21. (Pubitemid 47479889)